Heroin‐assisted treatment as a response to the public health problem of opiate dependence
Injection drug use (involving the injection of illicit opiates) poses serious public health problems in many countries. Research has indicated that injection drug users are at higher risk for morbidity in the form of HIV/AIDS and Hepatitis B and C, and drug‐related mortality, as well as increased cr...
Saved in:
Published in | European journal of public health Vol. 12; no. 3; pp. 228 - 234 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.09.2002
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Injection drug use (involving the injection of illicit opiates) poses serious public health problems in many countries. Research has indicated that injection drug users are at higher risk for morbidity in the form of HIV/AIDS and Hepatitis B and C, and drug‐related mortality, as well as increased criminal activity. Methadone maintenance treatment is the most prominent form of pharmacotherapy treatment for illicit opiate dependence in several countries, and its application varies internationally with respect to treatment regulations and delivery modes. In order to effectively treat those patients who have previously been resistant to methadone maintenance treatment, several countries have been studying and/or considering heroin‐assisted treatment as a complementary form of opiate pharmacotherapy treatment. This paper provides an overview of the prevalence of injection drug use and the opiate dependence problem internationally, the current opiate dependence treatment landscape in several countries, and the status of ongoing or planned heroin‐assisted treatment trials in Australia, Canada and certain European countries. |
---|---|
Bibliography: | istex:54A670A367B3B3213204EBED942020A3D4F8076C Received 7 May 2001. Accepted 3 December 2001. ark:/67375/HXZ-3WMTK6XJ-K local:120228 |
ISSN: | 1101-1262 1464-360X |
DOI: | 10.1093/eurpub/12.3.228 |